SCHEMBL10108893

SCHEMBL10108893

COc1ccc(C2=Cc3c(OC)cc(OC)cc3[C@@H]3CCC[C@H]23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.41
NOS1 P29475 2/20 0.41
NOS2 P35228 2/20 0.41
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAP2K3 P46734 1/20 0.35
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2E1 P05181 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP4B1 P13584 1/20 0.34
CYP2B6 P20813 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318246 1.00 NOS3 (0.41) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10109155 0.86 NOS3 (0.40) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL318483 0.86 NOS3 (0.40) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10109229 0.83 NPC1 (0.39) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL318434 0.83 NPC1 (0.39) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL10108856 0.80 NOS3 (0.47) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL317663 0.80 NOS3 (0.47) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL317691 0.78 PDE4A (0.35) NOS3NOS1NOS2PDE4APDE4B
SCHEMBL10109142 0.78 PDE4A (0.35) NOS3NOS1NOS2PDE4APDE4B
SCHEMBL317860 0.77 NOS3 (0.44) NOS3NOS1NOS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG NOS3 3463/4885NOS1 3050/4885NOS2 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.